HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grundy, S. M. Articles by Nestel, P. J. Search for Related Content PubMed PubMed Citation Articles by Grundy, S. M. Articles by Nestel, P. J. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 13, 531-551, July 1972
Copyright © 1972 by Lipid Research, Inc.

Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia

Scott M. Grundy , E. H. Ahrens Jr. , Gerald Salen , Paul H. Schreibman , and Paul J. Nestel

The Rockefeller University, New York 10021

The influence of clofibrate on cholesterol metabolism in patients with hyperlipidemia was studied by means of sterol balance and isotope kinetic techniques and by measurements of flow rates of cholesterol through the biliary tract. Long-term balance studies were carried out on a metabolic ward in 24 patients with all currently recognized types of hyperlipidemia; in five other patients with hypercholesterolemia, pool sizes and turnover rates of cholesterol were defined by compartmental analysis before and after three years' daily administration of the drug.

Except in fat-induced hypertriglyceridemia (two patients), clofibrate caused reduced plasma levels of triglycerides and cholesterol in all categories of hyperlipidemia. As a general rule, excretion of cholesterol into bile and feces was significantly increased and fecal bile acid excretion was decreased, regardless of the type of lipoprotein abnormality. Despite a net increase in steroid excretion in most patients with hyperlipidemia, cholesterol synthesis was not increased; indeed, in many patients synthesis appeared to be decreased. While the data obtained in 29 patients were not always consistent, the bulk of the evidence suggests that, in all forms of hyperlipidemia except fat-induced hyperglyceridemia, the drug causes an increased output of cholesterol while simultaneously inhibiting any compensatory increase in cholesterol synthesis. Therefore, it appeared that the increased excretion of steroids was most likely derived from cholesterol stored in tissues. This conclusion was strengthened by finding that long-term administration of the drug can cause marked reduction in body pools of cholesterol.

These findings are reflected clinically by resolution of skin and tendon xanthomatosis. However, it is not yet known whether the accumulation of cholesterol in arterial walls that is part of the process of atherogenesis can be inhibited or reversed by the drug.

Supplementary key words synthesis • absorption • excretion • tissue flux • biliary flow rates • pool sizes

Submitted on January 12, 1972
Accepted on April 4, 1972

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. M. Grundy Thyroid mimetic as an option for lowering low-density lipoprotein PNAS, January 15, 2008; 105(2): 409 - 410. [Full Text] [PDF]

				S. M. Post, H. Duez, P. P. Gervois, B. Staels, F. Kuipers, and H. M.G. Princen Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator-Activated Receptor-{alpha}-Mediated Downregulation of Cholesterol 7{alpha}-Hydroxylase and Sterol 27-Hydroxylase Expression Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1840 - 1845. [Abstract] [Full Text] [PDF]

				R.J. Courtenay Evans, A.N. Howard, and D.E. Hyams An Effective Treatment of Hypercholesterolaemia Using a Combination of Secholex(R) and Clofibrate Angiology, January 1, 1973; 24(1): 22 - 28. [PDF]

				M. C. Hunt, Y.-Z. Yang, G. Eggertsen, C. M. Carneheim, M. Gafvels, C. Einarsson, and S. E. H. Alexson The Peroxisome Proliferator-activated Receptor alpha (PPARalpha ) Regulates Bile Acid Biosynthesis J. Biol. Chem., September 8, 2000; 275(37): 28947 - 28953. [Abstract] [Full Text] [PDF]